Optimising the therapeutic efficacy of protein-based drugs against lymph-resident diseases

Kaminskas, Lisa, (Primary Chief Investigator (PCI))
Bulitta, Jurgen, (Chief Investigator (CI))
Porter, Christopher (Chief Investigator (CI))

Project: Research

Status	Finished
Effective start/end date	1/01/13 → 31/12/16

Funding

National Health & Medical Research Council (NHMRC): AUD336,056.00

Related content

Research Output

Conjugation of 10 kDa linear PEG onto trastuzumab Fab′ is sufficient to significantly enhance lymphatic exposure while preserving in vitro biological activity

Research output: Contribution to journal › Article › Research › peer-review

Spray-dried influenza antigen with trehalose and leucine produces an aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration

Research output: Contribution to journal › Article › Research › peer-review

Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration

Research output: Contribution to journal › Article › Research › peer-review

PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration

Research output: Contribution to journal › Article › Research › peer-review

PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice

Research output: Contribution to journal › Article › Research › peer-review